Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
CC transcript
INCYTE CORP (INCY) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/01/2018 BW Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs
04/13/2018 BW Incyte to Report First Quarter Financial Results
02/15/2018 BW Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs
01/31/2018 BW Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results
01/24/2018 BW Incyte to Report Fourth Quarter and Year-End Financial Results
12/14/2017 BW Incyte to Present at Upcoming Investor Conference
10/31/2017 BW Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs
10/24/2017 BW Incyte to Present at Upcoming Investor Conference
10/12/2017 BW Incyte to Report Third Quarter Financial Results
09/09/2017 BW Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
09/01/2017 BW Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month
08/30/2017 BW New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
08/01/2017 BW Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
07/11/2017 BW Incyte to Report Second Quarter Financial Results
06/05/2017 BW Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017
05/22/2017 BW Incyte to Present at Upcoming Investor Conferences
05/04/2017 BW Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
04/25/2017 BW Incyte to Present at Upcoming Investor Conferences
04/18/2017 BW Incyte to Report First Quarter Financial Results
02/21/2017 BW Incyte to Present at Upcoming Investor Conferences
02/14/2017 BW Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
06/04/2011 BW Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
05/24/2011 BW Incyte to Present at Upcoming Investor Conferences
05/03/2011 BW Incyte Reports First Quarter 2011 Financial Results and Program Updates
04/27/2011 BW Incyte to Present at the Bank of America Merrill Lynch Healthcare Conference
04/14/2011 BW Incyte to Report First Quarter 2011 Financial Results and Provide Update on Drug Discovery & Development Programs on May 3
04/05/2011 BW Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology Program
03/15/2011 BW Incyte's Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
02/23/2011 BW Incyte to Present at the Cowen and Company 31st Annual Health Care Conference
02/10/2011 BW Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives and Financial Guidance
11/10/2010 BW Incyte's Selective Oral JAK1 and JAK2 Inhibitor Demonstrates Positive Phase IIa Results in Patients with Active Rheumatoid Arthritis
11/10/2010 BW Incyte to Host Webcast at 2010 ACR/ARHP Annual Scientific Meeting
11/02/2010 BW Incyte Achieves $50 Million in Milestones for Initiation of a Joint Global Phase III Clinical Trial of Novel JAK1 and JAK2 Inhibitor INCB18424 in Patients with Polycythemia Vera
10/26/2010 BW Incyte to Report Third Quarter 2010 Financial Results and Provide Update on Drug Discovery & Development Programs on November 9
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy